NEW YORK – Roche announced on Tuesday that it has entered into an agreement with PathAI to develop digital pathology algorithms for companion diagnostics.
Under the agreement, PathAI will exclusively work with Roche Tissue Diagnostics to develop artificial intelligence-enabled digital pathology algorithms in the companion diagnostics space, Roche said in a statement. Roche Tissue Diagnostics will work exclusively with PathAI for a pre-specified term as the sole external algorithm development company for AI-based companion diagnostics. Roche will be able to continue developing its own algorithms for companion diagnostics, as well, while PathAI will continue to be able to freely develop algorithms outside of companion diagnostics, Roche noted.
In a separate statement, PathAI said the companies will create an integrated companion diagnostic assay, plus an algorithm development process, "to provide biopharma sponsors a seamless solution for AI-enabled companion diagnostics."
Image analysis algorithms developed through the partnership will be deployed through Roche's Navify digital pathology solution.
"This collaboration with PathAI will allow us to accelerate our ability to meet the demand from biopharma companies looking to develop AI-enabled companion diagnostics and provide them with a powerful end-to-end solution in the pursuit of precision therapeutics," Jill German, head of Roche Tissue Diagnostics, said in a statement.
The companies previously developed an embedded image analysis workflow for pathologists that allowed PathAI algorithms to be accessed within the Navify software platform.